Asia-Pacific To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC has identified six key trends for emerging biotechs to watch. For a full interview with Senthil Sockalingam, head of IQVIA…
Singapore Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies have greater access to funds, both from state actors as well as via private equity and public listings, but barriers…
Singapore ASLAN Pharmaceuticals is a clinical-stage immunology-focused biopharmaceutical company. CEO Dr Carl Firth reveals why the company has shifted its focus from oncology to autoimmune diseases. He explains why their lead asset has the potential to compete with Sanofi’s blockbuster Dupixent and why ASLAN decided to delist from the Taiwan Stock…
Singapore The CEO of ASLAN Pharmaceuticals, Dr. Carl Firth discusses the implications surrounding the company’s imminent initial public offering on Taiwan’s stock exchange, while explaining how this move serves to position ASLAN as Singapore’s first local success story. Having just completed a pre-IPO financing round, it seems the company has many…
Array The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the key differences between the industry in Taiwan and Singapore. ASLAN is busy setting up a subsidiary in Taiwan. What attracted…
ASLAN pharmaceuticals Why did you decide to start your own company? I started my career as a scientist with a real passion for molecular biology, and moved into pharmaceutical R&D working for AstraZeneca. After five or so years I was very keen to get commercial exposure, to see how we actually access…
See our Cookie Privacy Policy Here
